tbuckley/cabot-search huggingface dataset:
A French national network for rare head and neck cancers (REFCOR).
Authors: Bertrand Baujat, Anne Catherine Baglin, Frederic Chabolle, Valerie Costes Martineau, Francois Janot, Sylvie Testelin, Juliette Thariat, Emile Reyt
Journal: Journal of Clinical Oncology (2012)

e16013 Background: Squamous cell carcinomas of upper aerodigestive tract and endemic undifferenciated nasopharyngeal carcinomas are the most frequent head and neck (H&amp;N) cancers. Apart from these two entities, malignant H&amp;N tumors are uncommon due to their location and/or their histological type. They account for 10% of H&amp;N cancers (around 2,000 new cases/year in France). The rarity of these cancers limits the progress in all aspects. Treatments are based on low level scientific proofs. In most histological types, chemotherapy is uneffective. Prognosis is usually threatening. It was necessary to federate medical centers at a national level to enhance epidemiological knowledge, quality of patient management and to promote research projects. Methods: Structuration of the network included: 2008-2009: 4 working groups to edit recommandations of good practice in diagnosis and treatment of sinus cancers, salivary glands cancers, ear cancers, upper aerodigestive tract non squamous cell carcinoma cancers; 2009: A national database including sociodemographical, clinical, epidemiological, histological and follow-up data; 2009: Organization of biorepositories; 2010: A national group of expert pathologists for diagnosis advice (telepathology); 2011: Specialized multidisciplinary clinics at regional and national levels. Results: To date, 783 patients were included in the database by 29 centers. Tumor sites were sinus/nasal fossa (53%), Salivary glands (28%), Upper aerodigestive tract (18%), ear (1%). Stage at diagnosis repartition was 15% stage I, 24% stage II, 17% stage III, 44% stage IV. Main histological types are adenocarcinoma (17%), Adenoid Cystic carcinoma (9%), mucoepidermoid carcinoma (5%), muquous melanoma (5%). 337 biospecimens are referenced. Conclusions: The majority of french centers involved in H&amp;N cancers treatment contribute to this project. This network is a unique tool for improving the knowledge of rare H&amp;N tumors. Ongoing epidemiological studies will shortly be published. Translational studies based on biospecimens will follow. Collaboration with other networks such as the Salivary Gland Tumors Biorepository could be useful in the next future. Funding source: French National Institute of Cancer (INCa).
Outcome of HER2-positive breast cancer patients following metastatic relapse after adjuvant trastuzumab treatment since EMA regulatory approval.
Authors: Jean-Philippe Spano, Stéphane Vignot, Xuan Dung Ho, Nayi Zongo, Celine Magneux, Catherine Genestie, Thibault de la Motte Rouge, Jean-Pierre Lefranc, David Khayat, Joseph Gligorov
Journal: Journal of Clinical Oncology (2012)

641 Background: Trastuzumab, a humanized monoclonal antibody against human epidermal growth factor receptor 2 (HER2) is approved in France since 2005 for HER2-positive breast cancer patients in the adjuvant setting. Efficacy of this treatment is clearly established but little is known related to patient outcome if they develop metastatic relapse after adjuvant trastuzumab. The aim of this study is to analyse these relapses with a special focus on efficacy of anti-HER2 treatment in this setting. Methods: We analysed 456 patients with HER2-positive early breast cancer treated with trastuzumab containing adjuvant therapy between 2006 and 2011 in two Departments of Medical Oncology from Université Pierre et Marie Curie, Paris, France. Data from patients with metastatic relapse were identified. Disease free survival (DFS) between end of trastuzumab and relapse, quality of response, and time to progression after anti-HER2 new treatment are reported. Results: Relapse rate was 3.3 % after adjuvant trastuzumab (15 pts, median age 53 years, ER+ 40 %). DFS between end of trastuzumab and relapse was 244 days (95% CI: 91 - 397 days). One pt actually had a confirmed HER2-negative metastatic disease. The other 14 pts were treated with anti-HER2 agents at relapse. On 12 evaluable pts, an objective response was observed in 8 pts, stabilisation in 2 pts and progression in 2 pts. Median time to progression after first line metastatic treatment was 222 days (95% CI: 114 - 330 days). Additional data about site of relapse and subsequent therapies are available. Conclusions: Relapse after adjuvant trastuzumab remains a rare event in this real life cohort of breast cancer pts. For these pts, we will present data of the patterns of relapse and response. These data may help us to determine if adjuvant trastuzumab has an impact on outcome of HER2 metastatic disease compared to data in trastuzumab naive metastatic HER2-positive breast cancer pts. We also plan to seek international collaboration to expand our analyses, as well as overall survival.
Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
Authors: Maha Mamoor, Michael A Postow, Jessica A Lavery, Shrujal S Baxi, Niloufer Khan, Jun J Mao, Lauren J Rogak, Robert Sidlow, Bridgette Thom, Jedd A Wolchok, Deborah Korenstein
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Immune checkpoint inhibitors (CIs) have revolutionized treatment of advanced melanoma, leading to an emerging population of long-term survivors. Survivors’ quality of life (QOL) and symptom burden are poorly understood. We set out to evaluate symptom burden and QOL in patients with advanced melanoma alive more than 1 year after initiating CI therapy. Methods Cross-sectional surveys, accompanied by chart review of patients with advanced melanoma treated with CIs at Memorial Sloan Kettering Cancer Center, completed therapy, and were alive &gt;1 year after treatment initiation. Surveys were administered between February and August 2018. Surveys included: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, EuroQOL, items from Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events and Fatigue Severity Scale. Results We included 90 patients. The most common CI regimens were ipilimumab plus nivolumab (53%) and pembrolizumab (41%); most patients (71%) were not treated in clinical trials. Median time from CI therapy initiation was 40 months and from last dose was 28 months. Fatigue was reported by 28%, with higher fatigue scores in women than men; 12% reported difficulty sleeping. Aching joints (17%) and muscles (12%) were fairly common. Level of functioning was generally high. Overall QOL was excellent though 40% reported ‘some or moderate’ problems with anxiety/depression and 31% with pain/discomfort. Conclusions After CI therapy, long-surviving advanced melanoma patients commonly report fatigue but otherwise have moderate symptom burden and good QOL. Ensuring appropriate symptom management will optimize clinical outcomes for these patients.
Oral health in childhood as a predictor of future cardiovascular risk
Authors: Marta Czesnikiewicz-Guzik, Renata Górska
Journal: Cardiovascular Research (2020)

There is an increasing amount of evidence supporting the role of the immune system in aetiopathogenesis of cardiovascular diseases, ranging from atherosclerosis, through heart failure and hypertension. 1,2eriodontal disease is one of the most common chronic inflammation in the world population and has been associated with atherosclerosis and hypertension. 23][4] Other oral cavity pathologies, such as caries or periapical lesions, are also associated with cardiovascular risk. 5,6In this context, oral cavity could represent a critical culprit of lifetime or long-lasting exposure to inflammation, 7 that is likely initiated already in childhood, but exerts its effects in adulthood.This aspect is particularly important for primordial and primary prevention strategies that can bring substantial benefits through inexpensive oral hygiene education and encouragements.Unfortunately, there is a limited number of prospective, cohort studies of children and their follow-up through adulthood.The National Longitudinal Study of Adolescence to adult health followed-up 11 556 participants from baseline of 12-19 years of age until participants were 24-32 years old. 8Deferred dental care was associated with increased systolic [beta = 0.9; 95% confidence interval (CI) 0.4-1.5;P = 0.002] and diastolic (beta = 1.0; 95% CI 0.5-1.5;P < 0.001) blood pressure values and an increased likelihood of being hypertensive (odds ratio = 1.2; 95% CI 1.0-1.3;P = 0.03). 8Kelishadi et al. 9 showed data of nationwide population-based study conducted on 5258 Iranian students, aged 10-18 years.Unfortunately, the cohort was not followed prospectively but cardiometabolic risk factors were measured at the baseline.Higher frequency of tooth brushing was associated with lower mean levels of lowdensity lipoprotein cholesterol (LDL-C) (P < 0.0001) and lower frequency of elevated LDL-C in girls (P = 0.03).The frequency of elevated blood pressure decreased with higher tooth brushing frequency in boys (P = 0.03).After adjustment for potential cofounders such as age, gender, anthropometric indexes, socioeconomic status, and family history of non-communicable diseases, participants who brushed their teeth at
EFFECT OF SACUBITRIL/VALSARTAN VS. ENALAPRIL ON CHANGES IN BACKGROUND MEDICAL THERAPY OVER TIME IN THE PARADIGM-HF TRIAL
Authors: Ankeet Bhatt, Muthiah Vaduganathan, Brian Claggett, Jiankang Liu, Milton Packer, Akshay S. Desai, Martin Lefkowitz, Jean L. Rouleau, Victor Shi, Michael Zile, Karl Swedberg, Orly Vardeny, John McMurray, Scott D. Solomon
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF LIVER TRANSPLANTATION ON QT-INTERVAL IN PATIENTS WITH CIRRHOSIS
Authors: Anoop Ninan Koshy, Jefferson Ko, Omar Farouque, Hui-Chen Han, Han S. Lim, Benjamin Cailes, Paul J. Gow, Laurence Weinberg, Adam Testro, Andrew Teh
Journal: Journal of the American College of Cardiology (2020)
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure
Authors: Daxian Wu, Sainan Zhang, Zhongyang Xie, Ermei Chen, Qunfang Rao, Xiaoli Liu, Kaizhou Huang, Jing Yang, Lanlan Xiao, Feiyang Ji, Zhengyi Jiang, Yalei Zhao, Xiaoxi Ouyang, Danhua Zhu, Xiahong Dai, Zhouhua Hou, Bingjie Liu, Binbin Deng, Ning Zhou, Hainv Gao, Zeyu Sun, Lanjuan Li
Journal: Journal of Clinical Investigation (2020)

BACKGROUND. HBV-related acute-on-chronic liver failure (HBV-ACLF) is hallmarked by high short-term mortality rates, calling for accurate prognostic biomarkers for initial risk stratification.
ROLE OF CARDIAC COMPUTED TOMOGRAPHY FOR THE EVALUATION OF UNDERLYING ETIOLOGIES IN PATIENTS WITH NEWLY DIAGNOSED HEART FAILURE WITH REDUCED EJECTION FRACTION
Authors: Jong-Chan Youn, Dong Jin Im, Jin-Jin Kim, Ami Kwon, Sang Hong Baek, Seok-Min Kang, Hye-Jeong Lee
Journal: Journal of the American College of Cardiology (2020)
RATES OF FALLS AND RISK FACTORS ASSOCIATED WITH FALLS IN OLDER ADULTS WITH ATRIAL FIBRILLATION: FINDINGS FROM THE PROSPECTIVE SAGE-AF STUDY
Authors: Raghavendra Makam, Jane Saczynski, Wang Ziyue, Darleen Lessard, Kearney David, Catarina Kiefe, Jerry H. Gurwitz, Hamza Abu, Tanya Mailhot, Robert Joel Goldberg, David McManus
Journal: Journal of the American College of Cardiology (2020)
Suboptimal CPAP adherence: half a loaf is better than no bread at all
Authors: Martha E. Billings, Patrick Lévy, Najib Ayas
Journal: European Respiratory Journal (2020)

<b>Suboptimal CPAP use, less than 4 h per night, may still have beneficial effects on daytime sleepiness. Removing CPAP in those who routinely use it for 2–3 h a night worsened their daytime sleepiness.</b>http://bit.ly/36FjnF6
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)
Authors: Kevin R. Bainey, Robert C. Welsh, Stuart J. Connolly, Tamara Marsden, Jackie Bosch, Keith A.A. Fox, P. Gabriel Steg, Dragos Vinereanu, Derek L. Connolly, Scott D. Berkowitz, JoAnne M. Foody, Jeffrey L. Probstfield, Kelley R. Branch, Basil S. Lewis, Rafael Diaz, Eva Muehlhofer, Petr Widimsky, Salim Yusuf, John W. Eikelboom, Deepak L. Bhatt
Journal: Circulation (2020)

Background: The COMPASS trial (Cardiovascular Outcomes for People using Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily versus aspirin 100 mg once daily reduced the primary major adverse cardiovascular event (MACE) outcome of cardiovascular death, myocardial infarction, or stroke, as well as, mortality, in patients with chronic coronary syndromes or peripheral arterial disease. Whether this remains true in patients with a history of percutaneous coronary intervention (PCI) is unknown. Methods: In a prespecified subgroup analysis from COMPASS, we examined the outcomes of patients with a chronic coronary syndrome with or without a previous PCI treated with DPI versus aspirin alone. Among patients with a previous PCI, we studied the effects of treatment according to the timing of the previous PCI. Results: Of the 27 395 patients in COMPASS, 16 560 patients with a chronic coronary syndrome were randomly assigned to DPI or aspirin, and, of these, 9862 (59.6%) had previous PCI (mean age 68.2±7.8, female 19.4%, diabetes mellitus 35.7%, previous myocardial infarction 74.8%, multivessel PCI 38.0%). Average time from PCI to randomization was 5.4 years (SD, 4.4) and follow-up was 1.98 (SD, 0.72) years. Regardless of previous PCI, DPI versus aspirin produced consistent reductions in MACE (PCI: 4.0% versus 5.5%; hazard ratio [HR], 0.74 [95% CI, 0.61–0.88]; no PCI: 4.4% versus 5.7%; HR, 0.76 [95% CI, 0.61–0.94], P -interaction=0.85) and mortality (PCI: 2.5% versus 3.5%; HR, 0.73 [95% CI, 0.58–0.92]; no PCI: 4.1% versus 5.0%; HR, 0.80 [95% CI, 0.64–1.00], P -interaction=0.59), but increased major bleeding (PCI: 3.3% versus 2.0%; HR, 1.72 [95% CI, 1.34–2.21]; no PCI: 2.9% versus 1.8%; HR, 1.58 [95% CI, 1.15–2.17], P -interaction=0.68). In those with previous PCI, DPI compared with aspirin produced consistent (robust) reductions in MACE irrespective of time since previous PCI (as early as 1 year and as far as 10 years; P -interaction=0.65), irrespective of having a previous myocardial infarction ( P -interaction=0.64). Conclusions: DPI compared with aspirin produced consistent reductions in MACE and mortality but with increased major bleeding with or without previous PCI. Among those with previous PCI 1 year and beyond, the effects on MACE and mortality were consistent irrespective of time since last PCI. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01776424.
THE RELATIONSHIP OF OBESITY AND LOW HANDGRIP STRENGTH OR SARCOPENIC OBESITY AS A PREDICTOR OF THE PRESENCE OF CARDIOVASCULAR DISEASE
Authors: Jose Patricio Lopez, Patricio Lopez-Jaramillo, Paul A. Camacho, Darryl Leong, Sumathy Rangarajan, Salim Yusuf
Journal: Journal of the American College of Cardiology (2020)
EFFECT OF MYOCARDIAL ISCHEMIA IN DIABETIC AND NON-DIABETIC PATIENTS: LONG-TERM FOLLOW-UP OF MASS REGISTRY
Authors: Felipe Pereira Camara de Carvalho, Whady Hueb, Eduardo Gomes Lima, Jaime Linhares Filho, Matheus Ribeiro, Eduardo Martins, Daniel Valente Batista, Cibele Garzillo, Gustavo Andre Boeing Boros, Paulo Rezende, Fernando Faglioni Ribas, Carlos Serrano, Jose Ramires, Roberto Kalil-Filho
Journal: Journal of the American College of Cardiology (2020)
IDIOPATHIC LATE LEFT VENTRICULAR LEAD DISLODGEMENT LEADING TO PULMONARY EMBOLISM
Authors: Abhishek Bose, Zeba Hashmath, Padmastuti Akella, Sayf Altabaqchali, Adhirath Doshi, Parag Anilkumar Chevli, Sanjeev Goyal
Journal: Journal of the American College of Cardiology (2020)
Molecular analysis of pancreaticobiliary fine needle aspirate/duct brushing cytocentrifugation supernatant fluid.
Authors: Sydney D. Finkelstein, C. Max Schmidt, Eric M. Ellsworth, Valerie T. Stearns, Dennis M. Smith
Journal: Journal of Clinical Oncology (2012)

e21121 Background: Reliance on minimally invasive sampling techniques (fine needle aspiration (FNA), duct brushing) continues to increase for pancreaticobiliary (PB) pre-cancer/cancer diagnosis. Fundamental limitations include low cellularity, sampling variability, and indeterminate microscopic diagnosis. To address these issues, we developed a novel approach involving DNA mutational profiling of the soluble (or free) DNA in the cytocentrifugation supernatant fluid (supernatant) currently discarded during cytology preparation. Methods: 77 PB specimens underwent combined microscopic/molecular analysis using free DNA in cytology supernatant fluid. Pancreatic FNA and biliary cytobrushes had either surgical pathology or positive cytology as the gold standard. DNA was extracted from 2 mL of the supernatant and from corresponding microdissected cytology cells. Profiling included DNA quantity and quality, and analyses for KRAS mutations and 16 LOH (loss of heterozygosity) mutations. Results: The cell-free supernatant showed significantly higher levels of more intact amplifiable DNA than typical microdissection specimens. All non-neoplastic specimens (n=38) showed no false positive mutations. 37/39 malignant specimens showed mutations (sensitivity 95%, specificity 100%). Mutational profiles of the microdissected cells and the supernatant demonstrated high concordance. However, mutation detection was consistently superior in the supernatant fluid (mean 6.7 mutations) compared to the microdissected cells (mean 4.2). Mutation clonality was also significantly higher in the supernatant. Conclusions: Despite the lack of cells in many PB samples, the post-centrifugation supernatant fluid provides an abundant, robust, and highly representative source of DNA for molecular analysis. Of note, the greater extent and clonality of detected mutations in the supernatant fluid supports it being enriched with neoplastic DNA when cancer is present. This novel approach complements standard cytology practice by increasing sensitivity and specificity of cancer detection while reducing sampling variation.
CHRONIC TOTAL OCCLUSION OF THE LEFT MAIN CORONARY ARTERY IN AN UN-BYPASSED PATIENT PRESENTING WITH MINIMAL EXERTIONAL ANGINA
Authors: Luis Alonso Hernandez Mejia, Hardik M. Bhansali, Nader Hanna, Kevin Leung, Nicholas Ghiloni, Diana Miranda Ruiz, Jose Sleiman, Eduardo Perez, Elsy Navas, Kenneth Fromkin
Journal: Journal of the American College of Cardiology (2020)
Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma
Authors: T. Facon, J. Mary, J. Harousseau, F. Huguet, C. Berthou, B. Grosbois, B. Anglaret, A. Azzedine, P. Rodon, A. Peny
Journal: Journal of Clinical Oncology (2006)

1 Background: The standard MP regimen remains the reference treatment for elderly patients (pts) with multiple myeloma (MM). In May 2000, we initiated the IFM 99–06 trial, for pts aged 65–75 y, comparing MP (12 courses at 6 weeks intervals) to MP-THAL (MP plus THAL at the maximum tolerated dose, but ≤ 400 mg/day) and a MEL100-based treatment (VAD×2, CTX 3g/m 2 , and 2 courses of MEL100 mg/m 2 ). Methods: IFM99–06 was planned to enroll 476 evaluable pts, whose treatment allocation followed a 3 (MP), 2 (MP-THAL), 2 (MEL100) randomization scheme. The primary end-point was overall survival (OS). Secondary end-points were response to treatment and progression-free survival (PFS). Two interim analyses were planned and reviewed by a Data Safety Monitoring Board (DSMB) independent of IFM. At the second interim analysis, the DSMB suggested that a third interim analysis be performed with a date of point on May 1, 2005. Results: At this time, 436 pts had been enrolled, 191, 124 and 121 in MP, MP-THAL and MEL100 groups, respectively. The median (se) follow-up time was 32.2 (1.8) months (mo.). Median (se) PFS times were 17.2 (1.5), 29.5 (3.6) and 19.0 (1.3) mo. in MP, MP-THAL and MEL100 groups, respectively. The PFS time was significantly longer in the MP-THAL group than in the MP group (RR=2.4, P&lt;0.0001), but no significant difference was noted between MP and MEL100 groups (RR=1.2, P=0.12). There was a clear advantage in favor of MP-THAL vs MEL 100 (RR=2.0, P=0.0001). The PFS advantage in favor of MP-THAL translated to a significant benefit in terms of OS. Median (se) OS times were 30.3 (5.8) mo. (86 deaths), not reached at 56 mo.(34 deaths) and 38.6 (3.0) mo. (54 deaths) in MP, MP-THAL and MEL100 groups, respectively. The OS time was significantly longer in MP-THAL group than in MP group (RR=1.9, P=0.0008), but not significantly different between MP and MEL100 groups (RR=1.1, P=0.55). MP-THAL was also superior to MEL100 (RR=1.7, P=0.014). Conclusion: Since these results show the superiority of MP-THAL, enrollment was stopped. The final analysis will be presented at the meeting. MP-THAL should be, at the present time, the reference treatment for newly diagnosed MM pts ineligible for high-dose therapy. No significant financial relationships to disclose.
PREDICTORS OF IN-PATIENT MORTALITY IN PATIENTS ON SHORT-TERM LOW-DOSE INOTROPES FOR CARDIOGENIC SHOCK
Authors: Shuktika Nandkeolyar, Tanya Doctorian, Gary Fraser, Rachel Ryu, Whitney Kagabo, Colleen Fearon, David Tryon, Chris Hauschild, Liset Stoletniy, Dmitry Abramov, Anthony A. Hilliard, Antoine Sakr
Journal: Journal of the American College of Cardiology (2020)
Lung-targeted delivery of TGF-β antisense oligonucleotides to treat pulmonary fibrosis
Authors: Junghyun Kim, Seulgi Jeon, Seong Jae Kang, Kyoung-Ran Kim, Hien Bao Dieu Thai, Seokyung Lee, Sehoon Kim, Yun-Sil Lee, Dae-Ro Ahn
Journal: Journal of Controlled Release (2020)
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Authors: Azucena Salas, Cristian Hernandez-Rocha, Marjolijn Duijvestein, William Faubion, Dermot McGovern, Severine Vermeire, Stefania Vetrano, Niels Vande Casteele
Journal: Nature Reviews Gastroenterology & Hepatology (2020)
18O CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
Authors: A. Hollebecque, J.S. de Bono, S. Salvagni, R. Plummer, P. Niccoli, J. Capdevila, G. Curigliano, V. Moreno, F. De Braud, M. López-Brea, P. Martin-Romano, E. Baudin, M. Arias, J. De Alvaro, J. Parra-Palau, T. Sánchez-Pérez, I. Aronchik, E. Filvaroff, M. Lamba, Z. Nikolova
Journal: Annals of Oncology (2020)
41P Identifying novel target therapies for paediatric kidney cancer patients using patient-derived tumour organoids
Authors: C. Calandrini, S. Derakhshan, E.M. Dolman, R. De Krijger, L. Tytgat, J. Molenaar, M. Van den Heuvel-Eibrink, J. Drost
Journal: Annals of Oncology (2020)